Abstract: The present invention provides methods for treating, preventing, or delaying the onset of Charcot-Marie-Tooth Disease type 1A (CMT1A), by administering to a subject in need thereof a combination comprising baclofen, sorbitol and naltrexone, or a pharmaceutically acceptable salt thereof.

Abstract: The present invention provides methods for treating, preventing, or delaying the onset of Charcot-Marie-Tooth Disease type 1A (CMT1A), by administering to a subject in need thereof a combination comprising baclofen, sorbitol and naltrexone, or a pharmaceutically acceptable salt thereof.

Abstract: The present invention provides methods for treating, preventing, or delaying the onset of Charcot-Marie-Tooth Disease type 1A (CMT1A), by administering to a subject in need thereof a combination comprising baclofen, sorbitol and naltrexone, or a pharmaceutically acceptable salt thereof.

Abstract: The present invention provides methods for treating, preventing, or delaying the onset of Charcot-Marie-Tooth Disease type 1A (CMT1A), by administering to a subject in need thereof a combination comprising baclofen, sorbitol and naltrexone, or a pharmaceutically acceptable salt thereof.

Abstract: The present invention provides methods for treating, preventing, or delaying the onset of Charcot-Marie-Tooth Disease type 1A (CMT1A), by administering to a subject in need thereof a combination comprising baclofen, sorbitol and naltrexone, or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to a method for the treatment and/or prophylaxis of multiple sclerosis, and to the use of erythropoietin for this purpose and for the manufacture of a medicament for the intermittent treatment and/or intermittent prophylaxis of multiple sclerosis.

Abstract: The invention relates to various methods of detecting and analyzing protein interactions in a cell, which methods involve the appearance of a specific protein interaction being converted to a permanent detection signal by means of providing, in a manner dependent on said protein interaction, a recombinase activity or protease activity.

Abstract: The present invention relates to a method for the treatment and/or prophylaxis of multiple sclerosis, and to the use of erythropoietin for this purpose and for the manufacture of a medicament for the intermittent treatment and/or intermittent prophylaxis of multiple sclerosis.

Abstract: The invention relates to various methods of detecting and analyzing protein interactions in a cell, which methods involve the appearance of a specific protein interaction being converted to a permanent detection signal by means of providing, in a manner dependent on said protein interaction, a recombinase activity or protease activity.

Abstract: Described are various methods of detecting and analyzing protein interactions in a cell. The specific protein interaction is detected by a permanent signal generated by a recombinase activity or protease activity that depends on the protein interaction.

Abstract: For neurodegenerative diseases such as amyotrophic lateral sclerosis the prediction of disease progression or response to therapy based on phenotypic parameters is very difficult and inaccurate. The measurement of the serum protein carbonyl content allows a quantitative and early diagnosis of these diseases. It enables the monitoring of the disease progression as well as the individual adjustment of the therapy. Furthermore, this diagnostic marker can be used as a readout in animal model based screening methods for new therapeutic approaches and compounds.

Abstract: The present invention relates to the treatment of amyotrophic lateral sclerosis (ALS) and/or the improvement of motor function in individuals in need of such improvement using a melatonin compound or a pharmaceutical salt of the melatonin compound.

Abstract: The invention relates to a method of detecting and analyzing protein interactions in a cell, which comprises the steps: d) provision of the activity of at least one enzyme from the group consisting of recombinases and proteases in the cell as a result of a protein interaction, e) continual generation of an active reporter protein in the cell in question as a result of the enzymic activity of step a) for a period of time which exceeds the duration of the protein interaction of step a), f) generation of a detection signal by the reporter proteins generated in b). The invention furthermore relates to reverse embodiments of the method above of detecting and analyzing protein interactions in a cell, with, as a result of the induced dissociation of a defined interaction between proteins, the activity of at least one enzyme from the group consisting of recombinases and proteases being provided in the cell and converted to a permanent detection signal of said cell.

Abstract: The present invention relates to the treatment of amyotrophic lateral sclerosis (ALS) and/or the improvement of motor function in individuals in need of such improvement using a melatonin compound or a pharmaceutical salt of the melatonin compound.